retrovir trial [letter]

NLM AIDSLINE Retrovir trial [letter] Lehrman SN
June 30, 1989

Ann Emerg Med. 1989 Mar;18(3):330. Unique Identifier : AIDSLINE Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL Clinical Trials Human Occupational Diseases/PREVENTION & CONTROL Patient Care Team Zidovudine/*THERAPEUTIC USE CLINICAL TRIAL LETTER JOURNAL ARTICLE

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 COLORADO: Boulder Groups Honor More Than 150 Local AIDS Victims PENNSYLVANIA: Area Residents Screened for Hepatitis C on Sunday COLORADO: Peer to Peer: Teens Work to Educate Peers on Pregnancy, STDs at CCHS OREGON: Portland Barefoot 3 x 3 Benefit Tournament to Draw Hundreds to Northeast Portland TEXAS: Temple - Wellness and Sexual Health Classes Helping Kids to Abstain CONNECTICUT: Yale Researchers Urge More Street Work When Studying People With Both HIV, Hepatitis C JAMAICA: AIDS Awareness Workshop Organised for High-School Students EUROPE: EU Issues Stringent Sharps Regulations CALIFORNIA: $50,000 Prisoner Prescription: Inmates Get Expensive Hepatitis C Treatment Tentative approval of lamivudine and tenofovir disoproxil fumarate Tablets, 300 mg/300 mg Uganda: HIV Vaccine Trials to Start in July Experimental Gilead drug effective in early-stage leukemia trial TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events Jury to be seated, Vegas hep C trial due to start Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat HIV vaccine trial shut down HIV vaccine trial ends in failure: official Agency Halts Trial for AIDS Vaccine Jury selection starts in Vegas hepatitis C trial Boehringer Ingelheim's Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 Percent of Patients with Hepatitis C in Phase 3 Pivotal Trial
Information in this article was accurate in June 30, 1989. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.